ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases.
Priya KumthekarShou-Ching TangAndrew J BrennerSantosh KesariDavid E PiccioniCarey AndersJose CarrilloPavani ChalasaniPeter KabosShannon PuhallaKatherine H R TkaczukAgustin A GarciaManmeet S AhluwaliaJeffrey S WefelNehal LakhaniNuhad IbrahimPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Even though the study preset rule for iORR per IRF was not met in this heavily pretreated population, a notable CNS and systemic treatment effect was seen in all patients including symptom improvement and prolonged overall survival compared to historical control for the subset of patients with leptomeningeal carcinomatosis (n = 28).